NSE filing, NSE: ONESOURCE. Summary written from the filing by ALFA Finder's alert engine.
OneSource Specialty Pharma Ltd: key numbers
- Share price
- ₹1,558.20
- Market cap
- ₹17,868 Cr
- Revenue (annual)
- ₹1,422 Cr
- Net profit (annual)
- ₹-73.80 Cr
- P/E (TTM)
- -11022.9×Sector 45.9×
- Promoter holding
- 30.47%-0.01% QoQ
- FII holding
- 19.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from OneSource Specialty Pharma Ltd
All →OneSource Specialty Pharma Business Update
OneSource received a USFDA EIR with VAI classification for its Bengaluru SPD facility. This marks completion of the June 2026 inspection with no monetary penalty.
OneSource Specialty Pharma Earnings Call Transcript: Key Takeaways
Onesource Specialty Pharma delivered its third consecutive growth quarter, driven by new sterile cartridge capacity.
OneSource Specialty Pharma Results Update
OneSource announced Q2FY27 results with revenue up 37% YoY and EBITDA up 53% YoY. An investor presentation was filed alongside the press release.
OneSource Specialty Pharma Employee Stock Options
OneSource Specialty Pharma allotted 360 equity shares under its ESOP 2021 scheme to an eligible employee. Paid-up share capital increased to 11,46,74,151 shares of ₹1 each.
OneSource Specialty Pharma Management Change
Dr. Claudio Albrecht's designation changed from Independent Director to Non-Executive Non-Independent Director, effective 27 Oct 2026. The change is subject to shareholder approval at the upcoming meeting.
OneSource Specialty Pharma Q2 FY27 Results: Net Profit ₹57.5 Cr, Up 447.6% YoY
OneSource Specialty Pharma Ltd reported revenue from operations of ₹516.2 Cr (+37.4% YoY) and net profit of ₹57.5 Cr (+447.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹57.5 Cr · +447.6% YoY
Other adverse business impact announcements
All →Spandana Sphoorty Financial Adverse Business Impact
Cyber fraud debited ₹7.80 crore from Spandana Sphoorty's bank account on November 1, 2026. The company has reported to authorities and filed an insurance claim.
- Value
- ₹7.80 Cr
Medplus Health Services Adverse Business Impact
MedPlus Health Services' subsidiary Optival Health Solutions had its drug licence suspended for five days for a Suryapet store. Expected financial impact is about Rs 1.32 lakh.
- Value
- ₹0.01 Cr
- Execution
- 05 days
Oriental Rail Infrastructure Adverse Business Impact
Oriental Rail's subsidiary Oriental Foundry had a fire at its Kutch plant on 28 October 2026. Damage is minimal, operations are unaffected and the loss is insured.
Capillary Technologies India Adverse Business Impact
Capillary Technologies received KPMG's final forensic report on a cyber-enabled payment fraud at a step-down subsidiary. Four disputed payments totalled EUR 3.04 million, about Rs.32.24 Crore.
- Value
- ₹32.24 Cr
Windlas Biotech Adverse Business Impact
Windlas Biotech disclosed a cyber security incident on 30 October 2026. It states no material impact on core operations, finances or business continuity.
Neogen Chemicals Adverse Business Impact
Neogen Chemicals reports continued fire disruption at MPP3; replacement plant partly built with trial runs underway. Recognized damage totals ₹348.16 crore; production shifted to other sites.
- Value
- ₹348.2 Cr